Table 1.
Selected list of the ongoing clinical trials with nutlins/MDM2 inhibitors in AML and MDS
| Study ID | Disease | Drugs | Phase | Estimated completion date |
|---|---|---|---|---|
| NCT02670044 | R/R AML patients >60 years, not candidates for cytotoxic therapy | Venetoclax + idasanutlin or venetoclax + cobimetinib | Phase Ib/II | January 15, 2020 |
| NCT02545283 | R/R AML, 18 and older | Idasanutlin + cytarabine vs cytarabine alone | Phase III | May 26, 2021 |
| NCT03041688 | R/R AML, newly diagnosed AML | AMG-232 and decitabine | Phase Ib | October 31, 2019 |
| NCT03634228 | R/R AML | DS-3032b and cytarabine | Phase I/II | May 1, 2020 |
| NCT02319369 | R/R AML, newly diagnosed AML, high-risk MDS | DS-3032b ± azacitidine | Phase I | July 2021 |
| NCT03552029 | R/R AML with FLT3 mutation | DS-3032b + quizartinib | Phase I | October 15, 2021 |
| NCT02909972 | R/R AML and high-risk MDS with WT-TP53 | ALRN-6924 ± cytarabine | Phase I/Ib | April 2018 (Still listed as recruiting) |
Abbreviations: AML, Acute myeloid leukemia; MDS, myelodysplatic syndrome; R/R, relapsed/refractory.